Effect of compound glycyrrhizin injection on liver function and cellular immunity of children with infectious mononucleosis complicated liver impairment.
OBJECTIVE
To investigate the effects of Compound Glycyrrhizin Injection (CGI) on liver function and cellular immunity of children with infectious mononucleosis complicated liver impairment (IM-LI) and to explore its clinical therapeutic effect.


METHODS
Forty-two patients with IM-LI were randomly assigned, according to the randomizing number table, to two groups, 20 in the control group and 22 in the treated group. All the patients were treated with conventional treatment, but to those in the treated group, CGI was given additionally once a day, at the dosage of 10 ml for children aged below 2 years, 20 ml for 2-4 years old, 30 ml for 5-7 years old and 40 ml for 8- 12 years old, in 100-200 ml of 5% glucose solution by intravenous dripping. The treatment lasted for 2 weeks. T lymphocyte subsets and serum levels of alanine transaminase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBil) were detected before and after treatment. Besides, a normal control group consisting of 20 healthy children was also set up.


RESULTS
Baseline of the percentage of CD3 + , CD8 + lymphocyte and serum levels of ALT, AST, TBiL in the children with IM-LI were markedly higher, while the percentage of CD4 + lymphocyte and the CD4 + /CD8 + ratio was markedly lower in IM-LI children as compared with the corresponding indices in the healthy children ( P<0.01). These indices were improved after treatment in both groups of patients, but the improvement in the treated group was better than that in the control group (P<0.01).


CONCLUSIONS
Cellular immunity dysfunction often occurs in patients with IM-LI, and CGI treatment can not only obviously promote the recovery of liver function, but also regulate the immune function in organism.
Cao
Zong-xin
ZX
Department of Pediatrics, Central People's Hospital of Tengzhou City, Shandong (277500). tengzhouczx@163.com
Zhao
Zhong-fang
ZF
Zhao
Xiu-fen
XF
D002648:Child; D002675:Child, Preschool; D005260:Female; D019695:Glycyrrhizic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007223:Infant; D007244:Infectious Mononucleosis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D007267:Injections; D008099:Liver / Q000187:drug effects* / Q000503:physiopathology; D008107:Liver Diseases / Q000188:drug therapy*; D008297:Male; D016176:T-Lymphocyte Subsets / Q000187:drug effects
D019695:Glycyrrhizic Acid